| Revenue growth | 27.5% YoY growth in Q1FY27. |
|---|---|
| Margins | EBITDA margin 3.4%; impacted by high raw material prices and logistics. |
| Demand visibility | Growth momentum expected to continue in Blends across all geographies. |
Growth
Revenue grew 27.5% YoY; Specialty Ingredients rose 37%, Aroma grew 37%, and Straights increased 41%.
Outlook
Aims for Aroma breakeven soon; continuing growth momentum in Blends and stabilization of Vitafor and Vinpai acquisitions.
Risks
High raw material prices, elevated logistics costs, elongated working capital cycles, and lingering global conflicts impacting transit times.
Last quarter's promises, checked
Delivered
- Guided 2,200-2,400 MT Vanillin FY27 → delivered steady volumes (= BEAT)
- Guided Blends growth → delivered 17% growth (= BEAT)
- Guided CFS Europe cash burn to zero → delivered liquidation/gain (= BEAT)
Partly delivered
- Guided Vinpai/Vitafor breakeven → delivered stabilization phase (= PARTIAL)
Missed
- Guided 20% Blends growth → delivered 17-18% (= MISS)
- Guided double-digit margins → delivered 3.4% EBITDA margin (= MISS)
Investor Presentation filed with BSE, NSE: CAMLINFINE. Summary written with AI assistance from the document.
Camlin Fine Sciences Ltd: key numbers
- Share price
- ₹97.30
- Market cap
- ₹1,869 Cr
- Revenue (annual)
- ₹1,723 Cr
- Net profit (annual)
- ₹27.63 Cr
- P/E (TTM)
- 317.8×Sector 37.5×
- Promoter holding
- 48.03%+0.00% QoQ
- FII holding
- 0.91%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Camlin Fine Sciences Ltd
All →Camlin Fine Sciences Annual General Meeting
Camlin Fine Sciences filed a Postal Ballot Notice seeking approval to appoint Mr. Atul Pradhan as Non-Executive Independent Director. E-voting runs September 17 to October 16, 2026.
Camlin Fine Sciences Management Change
Camlin Fine Sciences appointed Mr. Atul Pradhan as Additional Non-Executive Independent Director effective September 11, 2026. The appointment is subject to shareholder approval via postal ballot.
Camlin Fine Sciences Earnings Call Transcript: Key Takeaways
Camlin Fine Sciences reported Q1 FY27 revenue of INR 5,199 million, up 28% YoY, though EBITDA margins were pressured to 4% by high raw material and freight costs.
- Call
- Guides 25% growth
Camlin Fine Sciences Q1 FY27 Results: Net Loss of ₹33.6 Cr, Loss Widens
Camlin Fine Sciences Ltd reported revenue from operations of ₹519.9 Cr (+27.5% YoY) and a net loss of ₹33.6 Cr for Q1 FY27.
- Key figure
- Net loss ₹33.6 Cr
Camlin Fine Sciences Earnings Call: Key Takeaways
Camlin Fine Sciences reported Q4 revenue of ₹424cr and FY26 revenue of ₹1,723cr. Strategy focuses on shifting from 'Straights' to 'Blends' and scaling Vanillin production.
Camlin Fine Sciences Earnings Call: Key Takeaways
CFS reported FY26 revenue of ₹17,233 mn (6% YoY growth) with an EBITDA margin of 6.2%. The company is pivoting towards high-value Blends and acquired Vinpai to diversify into natural ingredients.